LumellaPOC | Preeclampsia and Gestational Diabetes Point-of-Care Test
20631
home,page,page-id-20631,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,select-theme-ver-2.4,wpb-js-composer js-comp-ver-4.7.4,vc_responsive

The Lumella test, the new point-of care blood test helps in early detection of Preeclampsia

The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia.

 

The Lumella test requires a simple finger stick and can be performed in physician’s office/clinic in the first, second, or third trimesters, between 13 to 37 weeks of gestation.

Lumella_R1PE-(12-03-19)

Contact us: